Telehealth company Hims & Hers stirred up controversy by debuting a 2025 Super Bowl ad touting the benefits of its ...

Hims & Hers wants to keep on selling a compounded version of Ozempic. And it's channeling anti-establishment vibes to make its case.

Drug industry calls out telehealth company Hims & Hers' Super Bowl ad touting its knock-off weight loss medications.

Novo Nordisk sells the drug under the brand names Wegovy to treat obesity and heart disease and Ozempic to treat Type 2 diabetes. Compounding pharmacies are regulated by state boards of pharmacy ...

Novo Nordisk A/S shares are on track for their worst week this year, after a Super Bowl advertisement touting copycat ...

Viking Therapeutics (NASDAQ: VKTX) shares exploded higher after the clinical-stage drugmaker announced successful results ...

Two healthcare stocks in the white-hot weight-loss segment tanked on Monday as one of their rivals zoomed higher. The ...

Hims & Hers hit the bullseye with its Super Bowl ad, sparking a surge in clicks to its site.The ad also hit a nerve with the ...

The ad goes on to tout Hims & Hers' weight loss drugs as less expensive alternatives to medications like Ozempic and Wegovy, ...

The decliners were Novo Nordisk (NYSE: NVO), famously the company behind Wegovy, and Viking Therapeutics ... deserves kudos for being so bold in its marketing approach. I'm not convinced any ...

WEIGHT loss jabs slash alcohol cravings and can curb dangerous binge drinking, new research suggests.  The active drug ...